食管腺癌肿瘤免疫微环境决定了不同新辅助治疗模式的结局——来自 AGITG DOCTOR 试验和癌症进化生物样本库的结果

A plateau in treatment effect can be seen for the current 'one-size-fits-all' approach to oesophageal adenocarcinoma (OAC) management using neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT). In OAC, the tumour microenvironment (TME) is largely immunosuppressed, however a subgroup of patients with an immune-inflamed TME exist and show improved outcomes.

We aimed to understand the overall immune-based mechanisms underlying treatment responses and patient outcomes in OAC, and in relation to neoadjuvant therapy modality.

This study included 107 patients; 68 patients were enrolled in the Australian Gastro-Intestinal Trials Group sponsored DOCTOR Trial, and 38 patients were included from the Cancer Evolution Biobank. Matched pre-treatment and post-treatment tumour biopsies were used to perform multi-modality analysis of the OAC TME including NanoString mRNA expression analysis, multiplex and single colour immunohistochemistry (IHC), and peripheral blood mononuclear cell analysis of tumour-antigen specific T cell responses. Patients with the best clinicopathological outcomes and survival had an immune-inflamed TME enriched with anti-tumour immune cells and pathways.

Those with the worst survival showed a myeloid T regulatory cell enriched TME, with decreased CD8 + cell infiltration and increased pro-tumour immune cells. Multiplex IHC analysis identified that high intra-tumoural infiltration of CD8 + cells, and low infiltration with CD163 + cells was associated with improved survival.

High tumour core CD8 + T cell infiltration, and a low tumour margin infiltration of CD163 + cells was also associated with improved survival. nCRT showed improved survival compared with nCT for patients with low CD8 + , or high CD163 + cell infiltration. Poly-functional T cell responses were seen with tumour-antigen specific T cells.

Overall, our study supports the development of personalised therapeutic approaches based on the immune microenvironment in OAC. Patients with an immune-inflamed TME show favourable outcomes regardless of treatment modality.

However, in those with an immunosuppressed TME with CD163 + cell infiltration, treatment with nCRT can improve outcomes.

Our findings support previous studies into the TME of OAC and with more research, immune based biomarker selection of treatment modality may lead in improved outcomes in this deadly disease.